14:42 , May 20, 2019 |  BC Extra  |  Financial News

May 20 Financial Quick Takes: Schrödinger tops off E round; plus Mabpharm IPO update, DNA Script, ADMA Biologics, Storm

Schrödinger brings E round to $110M  Computational physics company Schrödinger LLC (New York, N.Y.) closed the second tranche of its total $110 million series E round to support development of its technology platform and expand...
11:10 , May 8, 2019 |  BC Extra  |  Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay...
14:36 , Mar 5, 2019 |  BC Extra  |  Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
22:12 , Dec 14, 2018 |  BioCentury  |  Finance

Spreading good Kurma

Declaring its last fund’s preseed partnership approach a success, Kurma Partners S.A. is expanding its model to build more new companies across Europe through its new Biofund III. For its 2016 Biofund II, the VC...
18:33 , Dec 14, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
15:40 , Dec 14, 2018 |  BC Extra  |  Financial News

Kurma announces first close of €150 million Biofund III

Kurma Partners S.A. completed the first close of its third fund, Kurma Biofund III, which is targeting a final close of €150 million ($169.4 million) in 2019. The firm declined to disclose the size of...
17:50 , Dec 7, 2018 |  BC Extra  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
06:15 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said on Aug. 9 it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed...
06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates,...
16:17 , Aug 9, 2018 |  BC Extra  |  Financial News

Novo Holdings leads Therachon's $60M round

Rare disease company Therachon AG (Basel, Switzerland) said it completed a $60 million mezzanine financing led by new investor Novo Holdings. Fellow new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital...